Korea’s first and only Medical Complex Incheon Sejong Hospital (Chairman Jinsik Park) is selected as the only medical institution in Incheon to engage in the Project for establishing and operating a residential treatment center dedicated to clinical trials for COVID-19 medicines, to be conducted by the Ministry of Health and Welfare (hereinafter referred to as MOHW).
​
 MOHW and the Korea National Enterprise for Clinical Trials (KONECT) carried out open recruitment this month for the Project for establishing and operating a residential treatment center dedicated to clinical trials for COVID-19 medicines. Five hospitals, including Incheon Sejong Hospital, were selected in an evaluation committee on December 17th this month.
​
 With the addition of five more hospitals to the existing clinical trial-only residential treatment centers of △Seoul Medical Center (Seoul) and △Eunpyeong St. Mary's Hospital (Seoul), a total of seven hospitals will be operating the centers.
​
While there is an urgent need to develop a domestic oral medication, it was difficult to carry out clinical trials due to insufficient spaces and hardships in recruiting patients as trials must be conducted in isolation from hospitals and facilities.
​ An official from MOHW said, "We will support the performing institution (cooperating hospital) to establish clinical trial infrastructure in the residential treatment center. After signing agreements and granting business expenses, we will be helping clinical trials in full swing early next year by supporting the association of domestic clinical trials for COVID-19 medications.” “We plan to support the recruitment of participants by prioritizing and assigning patients willing to undergo clinical trials for medications, depending on the severity, to residential treatment centers dedicated to clinical trials,” he added.
​
Incheon Sejong Hospital will receive dedicated personnel, equipment, and space to smoothly conduct clinical trials of COVID-19 medications for about one year until November 30, 2022 (Wednesday).
 ​
 Incheon Sejong Hospital BOD Chairman Park Jin-sik said, "With COVID-19 prolonged, the appearance of a mutated virus, and the number of confirmed cases increasing, the need to introduce an oral medication is increasing day by day. We will do our best to develop a safe and effective domestic medication in cooperation with other hospitals and the residential treatment centers,” he said.